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Abstract
N-Acetylglucosaminyltransferases III (GnT-III) and V (GnT-V) play a pivotal role in the processing of N-linked
glycoproteins, and are highly involved in cancer progression and metastasis. Expression of GnT-III and GnT-V in the liver is
enhanced during hepatocarcinogenesis, although they are not expressed in the normal liver. Gene expression of GnT-V is
regulated by a transcriptional factor, ets-1, which is involved in angiogenesis and invasion of tumor cells. When the
formation of the product of GnT-V, GlcNAc-L1-6 branches, is inhibited by overexpression of GnT-III, lung metastasis of
melanoma cells is suppressed. Modification of glycoprotein receptors such as the receptors for epidermal growth factor and
nerve growth factor by GnT-III sense transfection changes an intracellular signaling pathway, which may lead to a variety of
biological alterations in tumor cells. In this review, we focus on cancer progression and metastasis in relation to GnT-III and
GnT-V. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
It is well known that the structures of complex
carbohydrates are altered in cancer and that these
changes are highly associated with invasion and
metastasis. The mechanism by which those changes
occur are still unknown, but in most cases the acti-
vation of glycosyltransferases plays a major role and
this leads to so-called ‘aberrant glycosylation’ in can-
cer tissues [1]. The activities of the glycosyltransfer-
ases are mainly controlled by their gene expression
levels, substrate speci¢city toward donor and accept-
or molecules, and localization in organelles [2]. Re-
cent data obtained from the manipulation of glyco-
syltransferase genes have been utilized to explore the
mechanisms associated with malignant changes of
oligosaccharide structures and the signaling pathway.
In this mini-review, we will focus on the N-acetylglu-
cosaminyltransferases III and V, both of which play
a pivotal role in the branching of Asn-linked glyco-
proteins and their roles in invasion and metastasis of
cancer.
2. The N-acetylglucosaminyltransferases
The processing of N-glycans in the Golgi appara-
tus is the most important step in the biosynthesis of
the complex type of Asn-linked glycoproteins. It is
known that at least six N-acetylglucosaminyltransfer-
ases (GnTs), designated as GnT I^VI, are involved in
the biosynthesis of a core structure of the complex
type of N-glycans [2], as shown in Fig. 1. L1-3 N-
Acetylglucosaminyltransferases (iGnT) and L1-6 N-
acetylglucosaminyltransferases (IGnT) are responsi-
ble for generating peripheral structures, i.e., linear
and branched poly-N-acetyllactosamine backbones.
3. N-Acetylglucosaminyltransferase V
GnT-V catalyzes the formation of GlcNAc-L1-6
branches at the Man K1-6 side of the trimannosyl
core of N-glycans. These branches are abundant in
cancer tissues, especially in those with high meta-
static potential. In viral or oncogene-transformed ro-
dent ¢broblasts, branching at the trimannosyl core of
complex type N-glycans, especially the GlcNAc-L1-6
branch, is increased [3^5]. This increase contributes
to the elongation of N-glycans including poly-N-ace-
tyllactosamine structures, with associated sialyl Lex
and Lex structures known to be involved in cell-cell
interactions. Dennis et al. reported that a number of
di¡erent types of tumor cells which bind to the
L-PHA lectin have increased metastatic properties
[6]. These cells have an increase in GlcNAc-L1-6
Fig. 1. N-Acetylglucosaminyltransferases involved in complex
type N-glycans. GnT, N-acetylglucosaminyltransferase; Man,
mannose; GlcNAc, N-acetylglucosamine; Fuc, fucose; Asn, as-
paragine.
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linked branching of N-glycans, as judged by the
binding to L-PHA lectin which preferentially recog-
nizes the L1-6 branch structure, due to increased ac-
tivity of GnT-V. GlcNAc-L1-6 branch formation is
well correlated with the metastatic potential of tumor
cells such as human breast malignancies as judged by
the binding to L-PHA lectin. In addition, swainso-
nine, an inhibitor of N-glycan processing which
blocks the pathway prior to the initiation of the
L1-6 branching, also inhibits organ colonization by
MDAY-D2 cells and B16 melanoma cells [7,8].
Swainsonine is an inhibitor of K-mannosidase II
and was ¢rst isolated from Swainsona canescens, an
Australian plant that is toxic to animals and produ-
ces symptoms resembling those of human K-manno-
sidosis upon prolonged ingestion of this plant. There-
fore, swainsonine is used for preventing the
conversion of high mannose oligosaccharides into
those of the complex type in various mammalian
cell lines. Swainsonine treatment of either B16-F10
murine melanoma cells or MDAY-D2 murine lym-
phoreticular tumor cells resulted in a substantial im-
pairment of tumorigenic activity. Tumor cells cul-
tured in the presence of swainsonine for 24^48 h
showed reduced organ colonization potential when
they were injected into mice. These data also suggest
that GlcNAc-L1-6 branching or other complex N-
glycan structures may play a critical role in cancer
metastasis. GnT-V expression is induced by viral and
oncogene transformation [9] and during hepatocarci-
nogenesis in rats [10]. In cases of human hepatoma,
the GnT-V activity is well correlated with the severity
of the disease [11]. In addition GnT-V activity is also
augmented by phorbol esters and transforming
growth factor L1 [12]. Our group and other workers
independently puri¢ed the enzyme from human lung
cancer cells and rat kidney, respectively ,and cloned
the cDNA [13,14]. Messenger RNA was detected as
two bands in HepG2 and MCF7 cells [13], and LEC
rat liver [10], but the level was not always consistent
with enzymatic activity. To determine the details in
the up-regulation of GnT-V, analysis of the 5P-up-
stream regions of the GnT-V gene as well as post-
transcriptional modi¢cation were required.
3.1. Structure of the human GnT-V gene
We have isolated genomic DNA clones encoding
human GnT-V and reported that the human GnT-V
gene is divided into 17 exons, and that the open
reading frame is encoded by exons 2^17, spanning
155 kb [15]. Analysis of the 5P-untranslated regions
of mRNA from various cells showed multiple se-
quences depending on the cell types. Exon 1, which
was obtained by 5P-RACE using GOTO cell RNA as
a template, only contained a 5P non-coding region.
Exon 17 contained both coding and 3P non-coding
regions in the RNA, but the size of exon 17 is not
known because the GnT-V cDNA clone isolated did
not contain a poly(A) tail at its 3P end. The promoter
region of the GnT-V gene was characterized by
searching for any consensus sequences matching
those for transcription factor binding.
3.2. Identi¢cation of potential cis-regulatory
DNA sequences
Regions upstream from exon 1 and intron 1 ap-
pear to function as promoters. On sequence analysis
of the upstream region, a TATA box was found at
nucleotide position 327 from the start site of exon 1,
but a CCAAT motif was not found. A putative bind-
ing site for AP-1 which is a complex of proto-onco-
gene products Jun and Fos was observed at nucleo-
tide 3535. It is noteworthy that putative binding
sites for products of the Ets family (C/AGGAA/T)
and c-Myb (AACNG) were located at nucleotides
366, 3565 and 3728 and 3138 and 3287, respec-
tively, because GnT-V expression has been thought
to be related to malignant transformation. These re-
sults suggest that tissue-speci¢c expression of the hu-
man GnT-V gene may be regulated by activation of
tissue-speci¢c transcription factor binding sites iden-
ti¢ed in these 5P-upstream regions. Recombinant
plasmids containing variable lengths of putative pro-
moter and CAT reporter gene were transiently ex-
pressed in COS-1 cells, which is a mammalian cell
line expressing a large T antigen necessary for acti-
vation of the SV40 enhancer. The promoter activities
of pCAT-GV3 and pCAT-GV4 were lower than that
of the pCAT control vector, but approx. 13-fold and
1-fold higher than that of the pCAT enhancer vector,
respectively. Thus promoter activities of the 5P-up-
stream regions of exon 1 and of intron 1 were dem-
onstrated [16]. The consensus sequences for a TATA
box, AP-1, AP-2 and some other transcription fac-
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tors were found in the 5P upstream region of exon 1,
and consensus sequences for LF-A1, HNF1-HP1,
Ets-1 and liver-restricted transcription factors and
other factors were found in intron 1. The GnT-V
gene employs a multiple promoter system for its
transcription, and gene expression may be regulated
in a tissue-speci¢c and cell type-speci¢c manner as
shown in Fig. 2.
3.3. Identi¢cation of a functional regulatory element
within the 5P-untranslated regions of the human
GnT-V gene in HuCC-T1 cells
Saito et al. reported that the 5P-upstream regions
of both exon 1 and intron 1 exhibited promoter ac-
tivity when they were transiently expressed in COS-1
cells [15]. HuCC-T1 cell, a human bile duct carcino-
ma cell line, was also found to transcribe two types
of messages on 5P-rapid ampli¢cation of cDNA end
analysis (5P-RACE). To elucidate the transcriptional
mechanism for the human GnT-V gene in more de-
tail, in particular to identify functional elements nec-
essary for this cell line-restricted expression, GnT-V
activity was measured and two types of transcripts of
GnT-V were con¢rmed.
3.4. Regulation of the GnT-V is mediated by Ets-1
Deletion analysis indicated that the 31460/3710
and 3362/3243 regions of this promoter act as cis-
acting elements for HuCC-T1 restricted transcrip-
tion. We have shown that several putative binding
sites for LBP-1 (positions 31334, 31038, 3932),
AP-2 (positions 31264 and 3227), nuclear factor-
interleukin-6 (positions 31385, 31005, 3965, and
3255), c-myb (position 3287) and Ets-1 (positions
3728, 3565 and 3266) are included in these two
elements [15]. We chose to focus our analysis on
three putative binding sites for transcription factor
Ets-1, which is a product of proto-oncogenes related
to the malignant transformation and metastasis of
tumors as described below. To determine whether
or not the Ets-1 protein is able to bind to these
putative binding sites in the GnT-V gene regulatory
regions, gel mobility shift experiments were per-
formed using 23 bp GnT-V promoter-derived oligo-
nucleotides E266, E565, and E728, corresponding to
the three putative Ets binding sites in the 5P untrans-
lated regions of the GnT-V gene [16]. At ¢rst we
con¢rmed that the in vitro transcribed/truncated
Ets-1 protein and nuclear extracts of HuCC-T1 cells
indeed bind to the Ets-1 consensus sequence. Speci¢c
and high a⁄nity binding of the Ets-1 protein to the
Ets binding sites of the GnT-V regulatory regions
was demonstrated in competition experiments using
labeled E266 and E728 probes. This ¢nding suggests
that the Ets-1 protein recognizes the Ets consensus
sequence at positions 3266 and 3728. A gel mobility
shift assay using the same GnT-V promoter-derived
Ets binding sequence incubated with nuclear extracts
prepared from HuCC-T1 cells showed retarded pro-
tein-DNA complexes and, again, speci¢c binding was
identi¢ed on competition analysis. The addition of
anti-Ets-1 IgG resulted in competition with the pro-
tein-DNA complex whereas the mutated Ets binding
sequences did not compete. These results again re-
vealed the binding of an Ets-related factor to the 23
bp Ets binding site of the HuCC-T1 restricted pro-
moter region of the GnT-V gene.
3.5. Ets-1 as a transcription factor
The Ets transcription factor family shares a com-
mon DNA binding domain which interacts speci¢-
cally with sequences containing a common core tri-
nucleotide sequence, GGA [17]. Ets binding sites
have been identi¢ed in the regulatory regions of hu-
man T cell receptor-K [18] and -L [19], and interleu-
kin-2L receptor [20], as well as other cellular and
viral enhancers, and these Ets binding sites regulate
their transcriptional activities [21^26]. Ets-1 was ¢rst
described as a cellular homologue of v-ets in replica-
Fig. 2. Schematic drawing of the consensus sequence of the 5P
upstream region of GnT-V gene. Ets and AP-1 sites on the
GnT-V 5P £anking region are shown. Number indicates nucleo-
tide upstream from exon 1. The oligonucleotide probes used for
electrophoretic mobility shift assay are also indicated. An arrow
shows the position of the mutation on the nucleotide.
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tion-defective retrovirus E26 and is thought to be
associated with tumorigenesis and embryogenesis
[27]. The gene encoding ets-2 appears to be impor-
tant in cartilage/bone development and is one of the
major factors of Down’s syndrome [28]. The expres-
sion of c-ets-1 is associated with the invasion of tu-
mor cells in both in vitro and in vivo systems [29,30].
One possible mechanism by which Ets-related pro-
teins promote invasion of tumor cells is that they
enhance the transcription of matrix metalloprotein-
ase genes [31,32]. In contrast, Suzuki et al. [33] re-
ported that overexpression of the Ets-related protein
in colon cancer cells reversed the transformed phe-
notype and tumorigenicity. The presence of Ets bind-
ing sequences in the promoters of c-myc, and cdc-2
has also been reported. The c-myc and cdc-2 onco-
proteins have been implicated in the control of nor-
mal cell growth and their deregulation is associated
with neoplasia. From the above reports, expression
and regulation of these proteins are highly associated
with cancer invasion, metastasis and tumor cell
growth.
3.6. Regulation of the GnT-V promoter by Ets-1 in
various cancer cell lines
When the GnT-V gene was transfected into a lung
epithelial cell, the transfectant showed an increased
tumorigenicity, as evidenced by an assay involving
the subcutaneous injection of the cells into nude
mice [34]. This cell showed an altered ‘transformed
cell’ morphology as is often observed for oncogeni-
cally transformed cells. In addition, the overexpres-
sion of GnT-V decreased the serum growth require-
ments of the contact-inhibited parental cells, but
increased the migration rates of controls by 3^10-
fold, and the cells adhered less well to ¢bronectin
or collagen type IV. Ko et al. have investigated
whether the expression of GnT-V is correlated with
that of ets family mRNAs in 16 human and murine
cancer cells, and the e¡ects of overexpression of ets-1
and dominant-negative ets-1 on GnT-V expression,
as well as the coordination of AP-1 and GnT-V
genes [67]. Northern blot analyses were performed
on various cancer cell lines using ets-1, GnT-V, ets-
2, erg and £i-1 cDNAs as probes. Kato-III, HepG2,
Huh7, Colo201, Colo205 and B16-F1 cells showed
higher levels of ets-1 expression than the other cells.
The expression of GnT-V mRNA showed a pattern
similar to that for ets-1 expression. In contrast,
A549, Lu65A Lu99B, MKN45, PacaII, MB231,
Huh7, Hep3B and AH66 showed lower levels of
both GnT-V and ets-1 mRNA expression. Expres-
sion levels of GnT-V and ets-1 mRNA, quantitated
by densitometry, were plotted. A positive correlation
was found between these mRNAs expressed in can-
cer cell lines. This suggests that the GnT-V gene ex-
pression is controlled by ets-1 in various cell lines.
Although ets-2 has a motif similar to ets-1, the ets-2
expression pattern was di¡erent from the expression
of ets-1 and GnT-V. Erg, another protein of the ets
family, showed low expression levels in various cell
lines and did not correlate with GnT-V expression.
Expression of £i-1 which is known to be 98% homol-
ogous to erg showed a very similar pattern to erg.
To investigate expression of ets-1 and ets-2 at the
protein level, Western blot analysis was performed
using A549, B16-F1, HepG2 Huh7, Kato-III and
MKN45 cells. A high level of expression of ets-1
and ets-2 was observed in HepG2, Huh7 and Kato-
III cells. In contrast, their expression was quite low
in A549 cells, but high expression of ets-2 was ob-
served in MKN45 cells. These data were quite con-
sistent with their mRNA expression.
Nuclear extracts from MKN45, HepG2 and
Colo201 cell lines were subjected to electrophoretic
mobility shift assay (EMSA) analysis. This was per-
formed using a 24 bp GnT-V promoter-derived oli-
gonucleotide E728 (3741/3718), which was shown
to have moderate binding a⁄nity among the three
ets binding sites located in the 5P untranslated re-
gions of the GnT-V gene [16]. When the radiolabeled
oligonucleotide was incubated with nuclear extracts
prepared from MKN45, HepG2 and Colo201, re-
tarded protein-DNA complexes were detected. The
intensities of the complex of HepG2 and Colo201
were higher than that of MKN45. Speci¢city of bind-
ing was identi¢ed with a mutant oligonucleotide. In
order to con¢rm speci¢c binding, the supershift assay
was performed by the addition of anti-ets-1 and anti-
ets-2. While both antibodies were shown to super-
shift in the HepG2 cells, a supershifted band by the
ets-2 antibody was more clear than that of ets-1 anti-
body in MKN45 cells which express higher levels of
ets-2 than those of ets-1. The supershifted band by
ets-1 showed a competitive pattern in Colo201 cells.
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These results strongly re£ect the importance of ets-1
and ets-2 mRNAs in each cell.
3.7. Is AP-1 cooperative with ets-1 in GnT-V gene
expression?
Ets is already known to cooperate with AP-1 in
the transcriptional regulation of genes such as IL-2
[35], collagenase [36], and TNF [37]. To investigate
the cooperative trans-activation of c-Jun on the
GnT-V promoter throughout the c-Jun binding ele-
ment and the ets binding element, we ¢rst performed
Northern blot analysis in various cancer cell lines.
Expression of c-Jun mRNA was observed in nearly
all cells and was not correlated with GnT-V expres-
sion. To investigate directly the cooperation of AP-1
and ets binding elements on GnT-V expression,
EMSA was performed using a 58 bp GnT-V pro-
moter-derived oligonucleotide EJ565 (3578/3522),
which contained both ets and AP-1 sites. When the
radiolabeled EJ565 oligonucleotide was incubated
with nuclear extracts prepared from HepG2, the for-
mation of retarded protein-DNA complexes was ob-
served. When the radiolabeled MJ565, which con-
tained a mutant AP-1 site, and was designed to
detect the speci¢city of the AP-1 site, was incubated
with the nuclear extracts, the retarded protein-DNA
complex pattern was the same as when EJ565 was
used. Ets-speci¢c binding was con¢rmed using com-
petition analysis and the supershift assay. These re-
sults indicate that the DNA-protein complex with
E565 nucleotide was independent of AP-1 binding.
To further con¢rm that the AP-1 and ets-1 sites do
not cooperate, antisense c-Jun was transfected to
A549 and PacaII cells. Although these cells expressed
low levels of both ets-1 and GnT-V, the transfection
of a vector alone to these cells brought a slight en-
hancement of expression of GnT-V mRNA. When
antisense c-Jun was transfected into the cells, the
GnT-V mRNA expression was not changed, suggest-
ing that c-Jun is not linked to GnT-V expression.
3.8. The dominant negative ets-1 down-regulates
GnT-V gene expression
To demonstrate the enhancement of GnT-V by
ets-1 proteins by a di¡erent approach, the expression
of ets-1 was inhibited by the transfection of domi-
nant negative ets-1 in Kato-III and B16-F1 cells,
which showed high levels of intrinsic ets-1 and
GnT-V expression. When the dominant negative mu-
tant of ets-1 was transfected into Kato-III and B16-
F1 cells, the expression of GnT-V was decreased in
comparison with a mock transfection, suggesting
that ets-1 regulates GnT-V expression in these two
cell lines (Fig. 3).
3.9. Activation of GnT-V gene
As described above, GnT-V gene expression in
oncogenic transformation is probably mediated by
Fig. 3. A dominant negative ets-1 gene suppressed the expres-
sion of GnT-V gene. A dominant negative mutant of ets-1 was
transfected into Kato-III and B16-F1 cells which showed high
levels of GnT-V and ets-1 expression. 30 Wg of total RNA ex-
tracted from these cells were analyzed by Northern blotting.
Lane 1 indicates control plasmid pEGFP-N1, lanes 2 and 4 in-
dicate mock transfectants, and lanes 3 and 5 indicate transfec-
tants of the negative dominant mutant of ets-1. The mRNA of
the negative dominant ets-1 is indicated by an arrowhead. The
ethidium staining of the gel for equal amounts of RNAs is
shown in the bottom panel.
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the ets family including ets-1, a transcriptional factor
which also regulates several enzymes associated with
cell invasion and metastasis. This may up-regulate
the signaling pathway of cellular proliferation. This
pathway usually starts with growth factor receptors
with tyrosine kinase activities on the cell surface and
then proceeds through src, ras and raf signals, but
direct evidence for this is not available. The GnT-V
gene is activated by transfecting Ha-ras into NIH3T3
cells and EGF and insulin did induce the enzyme in
rat hepatocarcinoma cells [38]. Src also induces en-
zyme activity [39]. Very recently, Pierce’s group re-
ported that her-2/neu oncogene actually stimulates
the transcription of GnT-V in breast carcinoma cells
[40] and neu is mediated by the Ras-Raf-Ets signal-
ing pathway; this group previously reported that src
showed similar stimulation. From these data the
GnT-V gene is probably regulated by di¡erent recep-
tor tyrosine kinases.
3.10. Overexpression of GnT-V and GnT-V null mice
Dennis’s group reported that overexpression of
GnT-V in non-transformed Mv1Lu cells, an immor-
talized lung epithelial cell line, results in loss of con-
tact inhibition of cell growth, and this was totally
blocked by swainsonine, an inhibitor of K-mannosi-
dase II [34]. In serum-deprived and high density
monolayer cultures, the transfectants formed foci,
and typical characteristics of proliferating cells such
as maintained micro¢laments and also accelerated
cell death by apoptosis. Injection of the GnT-V
transfectants into nude mice produced a 50% inci-
dence of benign tumors and progressively growing
tumors as compared to the control group. In adhe-
sion assays, the GnT-V overexpressing cells in which
their sugar chains were modi¢ed, were less adhesive
on surfaces coated with ¢bronectin and collagen type
IV. The target proteins glycosylated by GnT-V gene
transfection were found to be LAMP-2 (lysosome
associated membrane protein 2), K5, KV and L1 in-
tegrins. These data suggest that GlcNAc-L1-6
branching of N-glycans contributes directly to re-
laxed growth controls and reduced substratum adhe-
sion in premalignant epithelial cells.
Very recently Dennis’s group generated GnT-V
null mice by homologous recombination in ES cells
[41]. GnT-V activity and L-PHA binding were absent
in all tissues examined. The mice had alterations in T
cell receptor (TCR) function, increased frequency of
intestinal crypts and decreased apoptosis in the intes-
tine. This is consistent with the ¢nding that the GnT-
V expression is known to be unregulated following T
cell activation. In the null mice, T cell surface glyco-
proteins underwent aberrant glycosylation and this
may result in the changes of physical association of
TCR, thus a¡ecting a change in the threshold of
agonist required for intracellular signaling. More in-
terestingly, when the GnT-V null mice were crossed
with polyoma virus middle T transgenic mice, the
frequencies of experimental breast cancer and tumor
metastasis were markedly reduced as compared to
controls [41]. These data also support the view that
GnT-V and its enzymatic product, the GlcNAc-L1-6
branch, play a pivotal role in cancer progression and
metastasis.
4. N-Acetylglucosaminyltransferase III
4.1. Competition of GnT-III and GnT-V in vivo leads
to suppression of cancer metastasis
GnT-III catalyzes the addition of GlcNAc via L1-4
linkage to the L-mannose of the mannosyl core of N-
glycans, and was originally identi¢ed in the hen ovi-
duct membrane [42]. It is well known that the bisect-
ing GlcNAc structure a¡ects the conformation of
sugar chains and after GnT-III acts on the bianten-
nary sugar chains other glycosyltransferases such as
GnT-II, GnT-IV and GnT-V are no longer able to
act on the biantennary sugar chains [43^45]. There-
fore GnT-III is a key enzyme in the biosynthesis of
N-glycans. In normal rat tissues, GnT-III activity is
abundant in kidney and brain but in the adult liver,
especially in hepatocytes, the enzyme activity is al-
most lacking. However, once the rat develops a pri-
mary hepatoma, the enzyme activity is rapidly in-
creased up to 100-fold or more. The same
phenomenon was observed in the case of ascites hep-
atoma cells [46]. A typical plasma membrane protein,
Q-glutamyltranspeptidase, is a glycoprotein and this
enzyme is also very low in adult rat liver but, again,
the activity is extremely high in the primary hepato-
ma or ascites hepatoma [47]. The Q-glutamyltrans-
peptidase catalyzes the degradation of glutathione,
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a major thiol antioxidant in the cells and the enzyme
belongs to the so-called second phase of drug metab-
olizing enzymes (see a review in [48]). The enzymes
were puri¢ed from adult rat kidney, adult rat liver
and ascites hepatoma and their carbohydrate struc-
tures were compared. The Q-glutamyltranspeptidase
puri¢ed from normal rat liver contains no bisecting
GlcNAc but the enzyme puri¢ed from primary hep-
atoma, ascites hepatoma or kidney contains a con-
siderable level of such residues in the enzyme [49].
These data are consistent with those of high activity
of GnT-III in rat primary hepatoma and ascites hep-
atoma as well as rat kidney and suggested that one of
the target glycoproteins in those tissues is Q-glutamyl-
transpeptidase.
Nishikawa et al. then puri¢ed the enzyme from
normal rat kidney using several chromatographic
procedures including substrate a⁄nity chromatogra-
phy and obtained a partial amino acid sequence of
the puri¢ed protein [50]. Oligonucleotide primers
were designed using amino acid sequences and a
cDNA was obtained. The mRNA of GnT-III is
highly expressed in rats with primary hepatoma [10]
and also in leukemia cells of patients [51]. As de-
scribed above, GnT-III regulates the further process-
ing of N-glycans and GnT-V expression is very
high in several tumor cells with high metastatic
potential.
We have studied whether or not GnT-III can mod-
ulate the expression of GnT-V activity in melanoma
B16 cells [52]. The experimental strategy was as fol-
lows. First we have isolated the high metastatic clone
of B16 melanoma cells and obtained B16 melanoma
F1hm cells. The enzymatic activity and mRNA ex-
pression of GnT-V were very high whereas those of
GnT-III were negligible if any. Then we made nine
transfectants of GnT-III which showed high GnT-III
gene expression. When we performed lectin blot
analyses on those transfectants and parental B16-
F1hm cells, L-PHA staining was very intense and
E-PHA staining was negligible in parental cells. On
the other hand, E-PHA staining was very strong and
L-PHA staining was negligible in the GnT-III trans-
fectants.
In order to know whether the transfectants did
a¡ect tumor metastasis and invasion, we have in-
jected both cells into the tail vein of mice and after
3 weeks we counted the number of colonies in the
lung due to metastasis. We found that lung meta-
stasis occurs very frequently in the parental cells,
but the GnT-III transfectants markedly reduce the
metastasis. In order to determine the mechanism by
which L-PHA binding in B16-F1hm was reduced by
GnT-III transfection, the molecular model of core
mannose in the presence and absence of bisecting
GlcNAc was made on an INDGO workstation using
Insight II/discover software on the basis of nuclear
magnetic resonance data [53]. The biantennary struc-
ture of a core mannose was twisted in the presence of
bisecting GlcNAc. These conformational changes
may be responsible for the substrate inaccessibility
to GnT-V to form the GlcNAc-L1-6 structure, which
raised the possibility that L1-6 branching may be
suppressed by the introduction of the GnT-III
gene. We also analyzed the substrate speci¢city of
GnT-V puri¢ed from human lung cancer cell lines
and con¢rmed that the bisected biantennary sugar
chain did not serve as a substrate for GnT-V, indi-
cating that once the GnT-III acts on the biantennary
structure of N-glycans, the GnT-V will not be able to
act.
We focused on important adhesion molecules such
as E-cadherin which play a major role in cell-cell
contact of cancer cells and contribute to invasion
of target tissues. When we examined the expression
of E-cadherin in the GnT-III transfectants, no di¡er-
ence in the mRNA levels was observed, but protein
levels of E-cadherin and its localization were dramat-
ically changed [54]. In the parental cells, E-cadherin
was weakly expressed at the cell-cell contacts, while
positive transfectants showed elevated expression at
cell-cell contacts. Moreover, pulse chase experiments
indicated that the half-life of E-cadherin in the pos-
itive transfectants is prolonged, that it was not
cleaved by proteolysis and was retained on the cell
surface membranes after a long period of time. This
indicates that the glycosylation of E-cadherin by
GnT-III occurs and this aberrant glycosylation of
E-cadherin may confer resistance to proteolysis, re-
sulting in the accumulation of E-cadherin at cell-cell
contacts. Overexpression of E-cadherin due to the
presence of the bisecting GlcNAc structures will
make tumor cells more tightly aggregate with each
other and prevent detachment from the lung meta-
static colony thereby promoting invasion into lung
tissues.
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4.2. Growth factor signaling and GnT-III
transfectants
GnT-III is highly expressed in brain and kidney
tissues. To examine the intracellular role of GnT-
III and its product in neural cells, the GnT-III
gene was overexpressed in a rat pheochromocytoma
cell line, PC-12 [55]. The GnT-III transfectants
showed a signi¢cant increase in E-PHA binding on
lectin blot analysis, indicating that some glycopro-
teins contained elevated levels of bisecting GlcNAc
structures. The parental cells were di¡erentiated into
sympathetic neurons upon treatment with nerve
growth factor (NGF) but the GnT-III transfectants
showed neither morphological response nor changes
in cell growth rate. In addition upon NGF treatment,
tyrosine phosphorylation of the Trk/NGF receptor
could not be detected in GnT-III transfected PC-12
cells, although the degree of NGF binding to control
and GnT-III transfectants remained unaltered. The
above study also showed that the modi¢cation of
Trk/NGF receptor as the result of the overexpression
of GnT-III in PC-12 cells, blocked ligand-induced
receptor dimerization. These results indicate that
the overexpression of the GnT-III gene in PC-12 cells
results in some aberrant glycosylation of the Trk
receptor which, in turn, a¡ects NGF-induced signal-
ing in PC-12 cells. Rebbaa et al. reported that the
binding of E-PHA lectin to the EGF receptor in
U373 MG human glioma cells blocks EGF binding
and receptor autophosphorylation [56]. In addition,
it has also been reported that overexpression of the
GnT-III gene in the U373 MG cells inhibits EGF-R
functions [57]. EGF-R is a glycoprotein and the oli-
gosaccharide residues play an important role in li-
gand binding, receptor clustering and the phospho-
rylation of its tyrosine residues. As described above,
we reported that overexpression of GnT-III in mouse
melanoma B16-F1 cells suppresses the metastatic po-
tential in vivo. The oligosaccharide structure of
EGF-R in GnT-III transfected B16-F1 mouse mela-
noma cells was modi¢ed. However, in contrast to
U373MG glioma cells, ligand-induced tyrosine kin-
ase activity of EGF-R was similar in both parental
and GnT-III transfected B16-F1 melanoma cells.
Further analysis of EGF-R speci¢c substrates
showed a signi¢cant phosphorylation of oncoprotein
c-cbl (J. Suresh et al., in preparation). Oncoprotein c-
cbl is a novel 120 kDa adapter protein which is im-
plicated in the regulation of PI3-kinase and MPK/
ERG pathways of signal transduction. We have also
shown that EGF-induced MEKs1 and 2 phospho-
rylation is inhibited in GnT-III transfected B16-F1
cells. Since MEKs are upstream kinases which phos-
phorylate and activate ERKs, we also observed the
down-regulation of EGF-induced ERK activation in
GnT-III transfected B16-F1 melanoma cells. The
MAP kinases are central transducers of transcyto-
plasmic signaling from hormones, growth factors,
cytokines and environmental stresses to the nucleus.
MAP kinase isoforms ERKs1 and 2 have been im-
plicated in the regulation of cellular proliferation and
di¡erentiation via the phosphorylation of transcrip-
tion factors and cytoskeletal proteins.
4.3. Transgenic mice and null mice of GnT-III genes
Cell speci¢c targets for GnT-III modi¢cation and
their di¡erential functions are so numerous that
GnT-III can be called a ‘multifacial glycosyltransfer-
ase’. In the normal rat liver GnT-III activity is nearly
undetectable, but during liver regeneration and hep-
atocarcinogenesis its activity is markedly increased
[10,58]. To determine the biological signi¢cance of
GnT-III in hepatocytes, transgenic mice which spe-
ci¢cally express GnT-III in the liver were established
[59]. The hepatocytes from transgenic mice showed a
swollen oval-like morphology with accumulation of
lipid droplets. In addition, circulating levels of tri-
glycerides, L- and pre-L-lipoprotein fractions (LDL
and VLDL) and apolipoprotein B100 were signi¢-
cantly reduced in the serum of transgenic animals,
compared to controls. However, apolipoprotein B
which contained an increased level of bisecting
GlcNAc accumulated in the transgenic hepatocytes.
Decreased levels of triglycerides in transgenic mice
plasma may also be related to the impairment of
microsomal triglycerides transport protein which
has two putative N-glycosylation sites. Collectively,
these data demonstrate that aberrant glycosylation,
as a direct result of the formation of bisecting
GlcNAc, disrupts certain functions of apolipoprotein
B such as its transport or lipoprotein complex for-
mation, leading to the generation of a fatty liver.
Marth and his colleagues developed GnT-III de¢-
cient mice by homologous recombination in ES cells
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and Cre-mediated gene deletion. The mice were
found to have no GnT-III activity as well as no re-
activity to E-PHA lectins. However, the GnT-III de-
¢cient mice were viable and reproduced normally. In
addition no abnormalities were found in brain and
kidney in which the GnT-III is highly expressed in
the wild mice [60]. However, very recently, Stanley
and her group have reported that GnT-III knockout
mice are resistant to diethylnitrosamine-induced tu-
morigenesis [61]. Stanley’s group investigated the
functional role of the bisecting GlcNAc in the devel-
opment of liver cancer. The GnT-III gene (Mgat3)
was inactivated by targeted gene disruption, and the
susceptibility of null mice (Mgat33=3) to tumor in-
duction was examined. After a single injection with
diethylnitrosamine and subsequent treatment with
phenobarbital for 6 months, the livers of the
Mgat33=3 mice were normal in size and only 50%
of mice had one to four small tumors, while the
Mgat3= or Mgat3=3 mice had enlarged livers
that contained numerous tumors. These data and
histological analyses indicated that tumor initiation
occurred in Mgat33=3 mice but tumor progression
was severely retarded.
These data suggest that GnT-III plays an impor-
tant role in the progression of preneoplastic foci to
primary hepatoma. However, hepatic tumor in
Mgat3= or Mgat3=3 mice showed low activity
of GnT-III. The authors suggested that a glycopro-
tein factor with bisecting GlcNAc structure facilitates
tumor progression in liver. Although such glycopro-
teins have not yet been found, cytokines or growth
factors produced by other cells may be responsible.
Another possibility arises that in the case of GnT-III
transgenic mice, sensitivity to a carcinogen such as
diethylnitrosamine may be increased and the animals
which overexpressed the GnT-III gene in the liver are
prone to have primary cancer in the liver. This ex-
periment is now underway in our laboratory.
4.4. Implication of GnT-III gene expression in various
cancers
GnT-III activity is also elevated in lymphoma cells
and in human leukemia cells especially in the state of
blast crisis [51]. A high level of activity of GnT-III
was observed in fetal liver but not in adult liver.
These data suggest that GnT-III may be linked to
undi¡erentiation. Treatment of hepatoma cells with
forskolin, an adenyl cyclase activator, increases GnT-
III gene expression while other agents or several cy-
tokines failed to induce GnT-III [62]. Interestingly,
induction of endogenous GnT-III by forskolin treat-
ment inhibited the sorting of membranous proteins,
lysosomal membrane glycoprotein 1 and Q-glutamyl-
transpeptidase. This indicates that bisecting GlcNAc
impairs the sorting toward the cell surface in a rat
hepatoma cell M31.
It is interesting to note that Q-glutamyltranspepti-
dase puri¢ed from rat hepatoma contains bisecting
GlcNAc [49], while the enzyme puri¢ed from human
hepatoma contains very little. Moreover, during hep-
atocarcinogenesis in rats, the enzyme activity in se-
rum is not markedly increased even though very high
activity is found in hepatoma tissue. On the other
hand, in serum and hepatoma tissues of patients
with primary hepatoma, enzyme activity is high (un-
published). This suggests that once the bisecting
GlcNAc is attached to Q-glutamyltranspeptidase, as
in the case of rats, the enzyme could not anymore
undergo sorting and will not be released to the plas-
ma.
Since GnT-III inhibits further processing of sugar
chains by other glycosyltransferases, the transfection
of GnT-III brought about tremendous biological
changes. For example, transfection of GnT-III into
K562 cells (a human erythroleukemia cell line) in-
creases their resistance to lysis by natural killer cells
and enhances their spleen colonization ability [63].
Transfection of GnT-III into a human hepatoma
cell line, HB611, which expresses hepatitis B virus
suppresses the expression of hepatitis B virus [64].
The mechanisms underlying these results require fur-
ther study. Aberrant glycosylation in£uences adhe-
sion molecule functions such as E-cadherin and
CD44, a ligand to hyaluronate. When GnT-III trans-
fected B16-F1 melanoma cells were injected into a
synergetic mice via tail vein, lung metastasis was sup-
pressed [52] because of increased E-cadherin levels on
their cell surface [54]. In contrast, when the same
cells were subcutaneously injected into the back of
mice, splenic colonization was promoted through oli-
gosaccharide remodeling of CD44 [65]. The spleen
contains abundant amounts of hyaluronate. The
GnT-III transfected cells had an increased a⁄nity
to immobilized hyaluronate and FITC labeled hya-
BBADIS 61871 13-9-99
N. Taniguchi et al. / Biochimica et Biophysica Acta 1455 (1999) 287^300296
luronate increased binding to the cell surface. The
enhanced adhesion in the cells was suppressed by
the treatment with L-N-acetylhexosaminidase, indi-
cating that N-acetylglucosamine residues were re-
sponsible for the enhanced adhesion. These data
demonstrate the multifacial functions of GnT-III in
tumor metastasis. Moreover, the role of bisecting N-
acetylglucosamine residues are quite di¡erent accord-
ing to the tissue and cell types. The reason why the
bisecting GlcNAc has multifactorial properties, is
that the regulation of the GnT-III gene expression
is controlled in a tissue- and cell-speci¢c manner.
5. Perspectives
In this review the implication of the GnT-III and
GnT-V genes and their roles in cancer including in-
vasion and metastasis were discussed. The earlier
works on structure and lectin binding assays for
the identi¢cation of GlcNAc-L1-6 branches and
also bisecting GlcNAc structures in the complex N-
glycans actually opened a new ¢eld of glycobiology.
The recent success in the puri¢cation of GnT-III and
GnT-V proteins and their cDNA cloning and gene
analyses could explain the pathophysiological signi¢-
cance of these genes. The analysis of upstream re-
gions of these genes prompted us to identify the tran-
scriptional factors and signaling molecules [66].
Moreover, the gene targeting technique has added
new insights into this ¢eld. The next step for eluci-
dating the actual function of these genes would be to
identify the target proteins when we have overex-
pressed the gene or knocked out the gene in vitro
or in vivo because the overexpression or knockout
of the glycosyltransferase genes would de¢nitely
change the carbohydrate structure of target proteins.
These issues suggest the possibility that the pheno-
typic changes observed in the gene targeting animals
were due to the secondary e¡ects, via the modi¢ca-
tion of carbohydrate structures in the target proteins.
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